Print Page | Sign In | Join
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 1 of 7
1  |  2  |  3  |  4  |  5  |  6  |  7

Scientific Advancements
Tuesday, May 14, 2019   (0 Comments - view/add)
Unexplored neural circuit modulates memory strength »
For Immediate Release Unexplored neural circuit modulates memory strength JUPITER, Fla. – May 14, 2019 — Learn...
Thursday, May 9, 2019   (0 Comments - view/add)
New Study Shows Catalyst CSR™ Total Shoulder System Provides Improved Accuracy and Precision in Rest »
New Study Shows Catalyst CSR™ Total Shoulder System Provides Improved Accuracy and Precision in Restoring Humeral Anatomy...
Monday, May 6, 2019   (0 Comments - view/add)
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Trea »
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Canc...
Monday, April 22, 2019   (0 Comments - view/add)
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Wo »
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Nov...
Monday, April 22, 2019   (0 Comments - view/add)
Axogen, Inc. Announces Completion of Planned Interim Analysis and One-Time Enrollment Expansion for »
Axogen, Inc. Announces Completion of Planned Interim Analysis and One-Time Enrollment Expansion for RECON® Study  ...
Wednesday, April 17, 2019   (0 Comments - view/add)
ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections »
ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections Download as PDF...
Wednesday, April 17, 2019   (0 Comments - view/add)
TherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S. »
TherapeuticsMD Announces Commercial Availability of BIJUVA ™ in the U.S. -BIJUVA is the only FDA-approved Therap...
Friday, April 12, 2019   (0 Comments - view/add)
OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial »
OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial   Apri...
Tuesday, April 9, 2019   (0 Comments - view/add)
FDA Approves Evenity™ (Romosozumab-Aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women A »
FDA APPROVES EVENITY™ (ROMOSOZUMAB-AQQG) FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK FOR FRACTU...
Monday, April 8, 2019   (0 Comments - view/add)
AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials »
AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials   GAINESVILLE, Fla., and CAMBRI...
Monday, April 1, 2019   (0 Comments - view/add)
FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin »
FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin   April 01, 2019 Approved for Use in th...
Wednesday, March 27, 2019   (0 Comments - view/add)
AdventHealth is the first in Florida to use state-of-the-art robotic technology for spinal procedure »
AdventHealth is the first in Florida to use state-of-the-art robotic technology for spinal procedures   M...
Thursday, March 21, 2019   (0 Comments - view/add)
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial »
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial   MIAMI, March 21, 2019 (GLOBE NE...
Wednesday, March 20, 2019   (0 Comments - view/add)
RTI Surgical Enrolls First Patient in FORTE Clinical Study of Fortilink® Interbody Fusion Device wit »
RTI Surgical Enrolls First Patient in FORTE Clinical Study of Fortilink® Interbody Fusion Device with TETRAfuse® 3D Techno...
Friday, March 15, 2019   (0 Comments - view/add)
Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial »
Oragenics, Inc. Announces Enrollment of 60 th Patient in Clinical Trial   March 15, 2019 04:17 PM East...
Friday, March 15, 2019   (0 Comments - view/add)
NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in »
NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA A...
Monday, March 11, 2019   (0 Comments - view/add)
Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Sta »
Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and A...
Tuesday, February 26, 2019   (0 Comments - view/add)
U.S. FDA Grants Market Clearance to Sensus Healthcare's New Sculptura™ Radiation Oncology System »
U.S. FDA Grants Market Clearance to Sensus Healthcare's New Sculptura™ Radiation Oncology System A Single Treatment dur...
Tuesday, February 26, 2019   (0 Comments - view/add)
Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the »
Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-E...
Monday, February 18, 2019   (0 Comments - view/add)
Research finds ethnoracial differences in Alzheimer’s disease »
Research finds ethnoracial differences in Alzheimer’s disease Feb. 18, 2019   A study led by Mayo r...
Friday, February 8, 2019   (0 Comments - view/add)
Scripps Florida scientists' bold strategy could help breast cancer patients »
Scripps Florida scientists' bold strategy could help breast cancer patients   By Marcia Heroux Pounds...
Thursday, February 7, 2019   (0 Comments - view/add)
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Pati »
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™ Provided Intravenously for Patients with Niemann-Pick...
Monday, January 28, 2019   (0 Comments - view/add)
Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716 »
January 28, 2018   Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716 &nbs...
Thursday, January 24, 2019   (0 Comments - view/add)
Espero BioPharma Provides Update on the Development of Tecarfarin
for the Treatment of Mechanical He »
Espero BioPharma Provides Update on the Development of Tecarfarin for the Treatment of Mechanical Heart Valve Patients in...
Thursday, January 17, 2019   (0 Comments - view/add)
Lakewood-Amedex Prepares To Launch A Phase 2 cDFU Clinical Trial for Its Nu-3 Antimicrobial In The B »
Lakewood-Amedex Prepares To Launch A Phase 2 cDFU Clinical Trial for Its Nu-3 Antimicrobial In The Bahamas  ...
Thursday, January 17, 2019   (0 Comments - view/add)
Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination »
Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug De...
Wednesday, January 16, 2019   (0 Comments - view/add)
AxoGen Announces RECON® Study Update »
AxoGen Announces RECON® Study Update Study Supports Company’s Planned Biologic License Application (BLA) for Avance® N...
Monday, January 7, 2019   (0 Comments - view/add)
KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydroco »
KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8...
Friday, January 4, 2019   (0 Comments - view/add)
Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phas »
Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating...
Wednesday, December 19, 2018   (0 Comments - view/add)
Mice no more? Hesperos’ Multi-organ “Human-on-a-Chip” System Found Effective for Long-Term Toxicolo »
Mice no more? Hesperos’ Multi-organ “Human-on-a-Chip” System Found Effective for Long-Term Toxicology Testing...
Friday, November 30, 2018   (0 Comments - view/add)
QIAGEN and NeoGenomics Collaborate to Offer Cancer Patients Day-One Access to Innovative Companion D »
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly a...
Thursday, November 29, 2018   (0 Comments - view/add)
FDA Approves Firdapse® (Amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) »
FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)   -...
Tuesday, November 20, 2018   (0 Comments - view/add)
LECOM Seeking Patients for an Innovative Research Study into Musculoskeletal Health »
LECOM Seeking Patients for an Innovative Research Study into Musculoskeletal Health Erie, PA. –November...
Monday, November 19, 2018   (0 Comments - view/add)
Rocket delivers cell samples to ISS to study effects of microgravity on muscles »
Rocket delivers cell samples to ISS to study effects of microgravity on muscles   Muscle cells from Flori...
Thursday, November 15, 2018   (0 Comments - view/add)
Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Pha »
Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of...

Displaying page 1 of 7
1  |  2  |  3  |  4  |  5  |  6  |  7

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect